Pradefovir mesilate. Treatment of hepatitis B

Drugs of the Future

Volumn 32, Issue 2, 2007, Pages 137-143

  Sorbera, L A ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; MB 06866; PLACEBO; PRADEFOVIR MESILATE; REMOFOVIR; TELBIVUDINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG RESEARCH; DYSPEPSIA; ENZYME INHIBITION; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 34247512490     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.02.1075008     Document Type: Review

References (42)

1. Kopcho, J.J., Matelich, M.C., Reddy, K.R., Ugarkar, B.G. (Metabasis Therapeutics, Inc.). Process for preparation of cyclic prodrugs of PMEA and PMPA. JP 2005525422, US 2003225277, WO 2003095665.
2. Erion, M.D., Kopcho, J.J., Matelich, M.C., Reddy, K.R. (Metabasis Therapeutics, Inc.). Novel phosphonic acid based prodrugs of PMEA and its analogues. EP 1532157, US 2003229225, WO 2004037161.
3. Reddy, K.R., Matelich, M.C., Ugarkar, B.G. et al. HepDirect™ prodrugs of adefovir: Design, synthesis and optimization. 227th ACS Natl Meet (March 28-April 1, Anaheim) 2004, Abst MEDI- 27.
4. Martin, K. (Metabasis Therapeutics, Inc.). Lewis acid mediated synthesis of cyclic esters. CA 2565966, EP 1753762, US 2005282782, WO 2005123729.
5. 450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phospho(on)ate-based drugs to the liver. J Am Chem Soc 2004, 126(16): 5154-63.
6. Prous Science Disease Briefings: Hepatitis B (online publication). Updated 2007.
7. Hepatitis B Foundation. What is hepatitis B? Statistics.
8. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11(2): 97-107.
9. Ganem, D., Prince, A.M. Hepatitis B virus infection - Natural history and clinical consequences. New Engl J Med 2004, 350(11): 1118-29.
10. Lok, A.S. New treatment of chronic hepatitis B. Semin Liver Dis 2004, 24(Suppl. 1): 77-82.
11. Marcellin, P. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003. 348(9): 808-16.
12. Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., Pastore, G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000, 32(2): 300-6.
13. Wong, D.K. et al. Effect of alpha-interferon treatment in patients with hepatitis B e positive chronic hepatitis B. A meta analysis. Ann Intern Med 1993, 119(4): 312-23.
14. Graul, A., Castañer, J. BMS-200475. Drugs Fut 1999, 24(11): 1173-7.
15. Sorbera, L.A., Castañer, J., Castañer, R.M., Bayés, M. Telbivudine. Drugs Fut 2003, 28(9): 870-9.
16. Balzarini, J., Hao, A., Herdewijn, P., Johns, D.G., De Clercq, R. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent antihuman immunodeficiency virus compound. Proc Natl Acad Sci USA 1991, 88(4): 1499-503.
17. Cundy, K.C., Shaw, J.P., Lee, W.A. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys. Antimicrob Agents Chemother 1994, 38(2): 365-8.
18. Cundy, K.C., Barditch-Crovo, P., Walker, R.E., Collier, A.C., Ebeling, D., Toole, J., Jaffe, H.S. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type I-infected patients. Antimicrob Agents Chemother 1995, 39(11): 2401-5.
19. Heathcote, E.J., Jeffers, L., Perrillo, R. et al. Serum HBV DNA suppression and seroconversion following long-term ade fovir dipivoxil therapy in chronic hepatitis B patients. Hepatology 2001, 34(4, Part 2): Abst 577.
20. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3885B1_01_Gilead.pdf
21. Erion, M.D., van Poelje, P.D., MacKenna, DA. et al. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005, 312(2): 554-60.
22. van Poelje, P.D., Colby, T.J., Fujitaki, J.M. et al. MB6866 (Hepavir B), a HepDirect™ prodrug of adefovir: Mechanism of activation and liver targeting. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24-28, Boston) 2003, Abst 1143.
23. Reddy, K.R., Gomez-Galeno, J.E., Lemus, R.H., Colby, T.J., van Poelje, P.D., Erion, M.D. MB06886 (Hepavir B), a HepDirect™ prodrug of adefovir: Mechanism of activation and liver targeting. 227th ACS Natl Meet (March 28-April 1, Anaheim) 2004, Abst MEDI-28.
24. Reddy, K.R., Ugarkar, B.G., Matelich, M.C. et al. Hepavir B (MB06866): A novel hepatitis B antiviral therapy using the HepDirect™ prodrug technology for targeting adefovir to the liver. 227th ACS Natl Meet (March 28-April 1, Anaheim) 2004, MEDI-342.
25. Erion, M.D., Colby, T.J., Reddy, K.R. et al. HepDirect™ prodrugs A novel strategy for targeting drugs to the liver. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1-5, Boston) 2002, Abst 551.
26. Lin, C.-C., Fang, C., Benetton, S., Xu, G.-F., Yeh, L.-T. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother 2006, 50(9): 2926-31.
27. Srivastava, P., Li, C., Fang, C., Turk, R., Lin, C.-C. Evaluation of potential of cytochrome P450-mediated drug interactions with Hepavir B and adefovir dipivoxil. Drug Metab Rev 2003, 35(Suppl. 2): Abst 352.
28. Lin, C.-C., Fang, C., Benetton, S., Yeh, L.-T. Pradefovir is a substrate, but neither an inhibitor nor an inducer for cytochrome P450. 56th Annu Meet Am Assoc Study Liver Dis (Nov 11-15, San Francisco) 2005, Abst 811.
29. Lin, C.-C., Yeh, L.-T., Vitarella, D., Hong, Z., Erion, M.D. Remofovir mesylate: A prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antiviral Chem Chemother 2004, 15(6): 307-16.
30. 14C]remofovir in rats and cynomolgus monkeys. Antimicrob Agents Chemother 2005, 49(3): 925-30.
31. Lin, C.-C., Xu, C., Teng, A., Yeh, L.-T., Peterson, J. Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J Clin Pharmacol 2005, 45(11): 1250-8.
32. Xu, C.R., Teng, A., Lin, C.-C., Yeh, L.-T. Absence of food effect on the extent of exposure of pradefovir in healthy adult volunteers. 35th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 17-19, Cambridge) 2006, Abst 60.
33. Fang, C., Lim, C., Srivastava, P., Lau, J.Y., Lin, C. Liver-targeting prodrug of PMEA induces a much more favorable kidney and liver toxicological gene expression in rats compared to BisPOM-PMEA. 42nd Annu Meet Soc Toxicol (March 9-13, Salt Lake City) 2003, Abst 1274.
34. Lau, D., Nguyen, T., Tong, M. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of remofovir in chronic HBV patients in US and Canada following daily dosing for 28 days. 40th Annu Meet Eur Assoc Study Liver (April 13-17, Paris) 2005, Abst 74.
35. Lin, C.-C., Chao, Y.-C., Lai, M.-Y. et al. Safety, tolerance, pharmacokinetics and pharmacodynamics of remofovir, a liver-targeting prodrug of PMEA in HBV patients following daily dosing for 28 days. Hepatology [55th Annu Meet Am Assoc Study Liver Dis (Oct 29-Nov 2, Boston) 2004] 2004, 40(4, Suppl. 1): Abst 1141.
36. Lin, C., Xu, C., Yeh, L., Sullivan-Bolyai, J., Xu, Y. Pharmacokinetics and pharmacodynamics of pradefovir, a liver-targeting prodrug of PMEA in HBV patients. 41st Annu Meet Eur Assoc Study Liver (April 26-30, Vienna) 2006, Abst 36.
37. Lee, K.S., Lim, S.G., Chuang, W.L. et al. Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-Week analysis of a phase 2 study. 41st Annu Meet Eur Assoc Study Liver (April 26-30, Vienna) 2006, Abst 741.
38. Sullivan-Tolyai, J., Lim, S.G., Lee, K.W. et al. Safety, tolerability, antiviral activity, and pharmacokinetics of pradefovir mesylate in patients with chronic hepatitis B virus infection: 24-Week interim analysis of a phase 2 study. 56th Annu Meet Am Assoc Study Liver Dis (Nov 11-15, San Francisco) 2005, Abst LB07.
39. Dose-ranging study of pradefovir patients with compensated hepatitis B (NCT00230503). ClinicalTrials.gov Web site, February 6, 2007.
40. Open-label treatment extension study for patients who complete study RNA200103-201 (NCT00230490). ClinicalTrials.gov Web site, February 6, 2007.
41. Lin, C.-C., Teng, A., Yeh, L.-T., Vitarella, D., Hong, Z., Erion, M. Development of Hepavir B, a prodrug of PMEA with excellent liver-targeting properties. J Hepatol 2004, 40(Suppl. 1): Abst 374.
42. 14C]Hepsera in rats and monkeys. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24-28, Boston) 2003, Abst 1193.